RBMX and thyroid gland papillary carcinoma: Mutations in RBMX were recently reported in papillary thyroid carcinoma cells resistant to vemurafenib [94], and knock-down of wild-type RBMX caused an increase of p-AKT protein level in naïve cancer cells.